ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

PubMedID: 25921280

Ma CX, Sun YH, Wang HY. ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. Tumour Biol. 2015;.
THE AIM
of this study is to investigate the association of ABCB1 polymorphisms with susceptibility to adult acute leukemia, and the influence of ABCB1 polymorphisms on the efficacy of high-dose methotrexate (HDMTX).The aim of this study is to investigate the association of ABCB1 polymorphisms with susceptibility to adult acute leukemia, and the influence of ABCB1 polymorphisms on the efficacy of high-dose methotrexate (HDMTX). ABCB1 polymorphisms in 178 acute leukemia patients (case group) and 150 healthy subjects (control group) were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. All patients received HDMTX therapy. Correlation analysis was performed to explore the associations of ABCB1 polymorphisms with MTX concentration and efficacy of MTX therapy. All statistical analyses were conducted with SPSS 19. 0 software. The frequency of TT genotype and T allele on ABCB1 3435C?>?T in case group were significantly higher than the control group (P??T/A (P?>?0. 05). Furthermore, 24-h MTX concentration of patients carrying TT and TA genotypes on 2677G?>?T/A was higher than carriers with other genotypes (P??T was also apparently higher than carriers with CC genotype (P??T/A was markedly lower than carriers with non-GG genotype (P??T polymorphisms may be associated with susceptibility to acute leukemia, and ABCB1 polymorphisms might be a sensitive indicator for predicting efficacy of MTX therapy in the treatment of acute leukemia.